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Background

The ideal practice for patients requiring metered-dose inhalers (MDI) with coronavirus
disease 2019 (COVID-19) is to use patient specific MDIs. However, this practice may not be
possible during a time of increased usage throughout the country and limited availability of
the medication. Nebulized medications are a concern due to the potential for aerosolized
virus and increased exposure for health care workers. An alternative program of canister
reassignment is proposed to address concerns for infection prevention, cross-contamination
of MDI canisters and the shortage of MDI’s due to the COVID-19 pandemic.
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Methods

A comprehensive MDI canister reassignment process was developed for facilities affiliated
with a large health care system in response to the COVID-19 pandemic. The MDI canister
reassignment process consisted of 4 components: preservation of supply, reassignment
workflow, canister cleaning and operational integration. Albuterol MDI administration data
was monitored from January 1st to August 31st, 2020.

Results

Following development and rapid implementation of a comprehensive canister
reassignment process, albuterol MDI administration data was reviewed from 162 hospitals
affiliated with a large health care system. At baseline (prior to the COVID-19 pandemic),
98% of patients received a nebulizer vs. an MDI. After the implementation of the MDI
reassignment process (during the COVID-19 pandemic), nebulizer usage decreased by 60%
from March 6th to March 31st and was sustained with >50% reduction through August 31st.

Conclusion

MDI canister reassignment was an instrumental process to allow the continued delivery
of pharmacologic bronchodilator therapy for COVID-19 patients. It also represents an
important infection prevention strategy needed to protect our health care providers from
the potential aerosolized virus associated with nebulizers.
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Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus first
identified in late 2019 that led to a pandemic
designated by the World Health Organization

as coronavirus disease 2019 (COVID-19). With
ongoing efforts to understand COVID-19 and
determine optimal treatment for affected patients, it is important to develop enhanced response and preparedness strategies to address
critical needs.
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Patients with severe COVID-19 may develop
acute respiratory distress syndrome (ARDS)
requiring mechanical ventilation. However,
patients with ARDS often do not respond to
treatment with bronchodilators unless there
is the presence of an underlying chronic respiratory disease, such as asthma or chronic
obstructive pulmonary disease (COPD).1,2 In
a meta-analysis, COPD was among the most
common types of comorbidities found in
COVID-19 patients.3 Patients with underlying
conditions were also found to have worse outcomes.4
Administration of nebulized medications is
associated with generating aerosolized particles.5-7 While some may consider it controversial, there is concern for an increased risk of
disease transmission with the use of nebulizers
in patients with COVID-19 and may put health
care workers (HCW) at increased risk.5-7 To
minimize aerosolized particles and the subsequent spread of disease as well as protect
our HCW, a metered-dose inhaler (MDI) is the
recommended delivery device if bronchodilator
use is necessary for the treatment of patients
with a confirmed or suspected COVID-19
infection.8 With the nationwide supply of
MDIs compromised due to increased demand,
bronchodilator therapy should be reserved
for those patients where it will be the most
effective. Therapy should be prioritized for
patients with chronic respiratory disease or for
the treatment of patients with ongoing bronchoconstriction, increased airway resistance or
obstruction. The need for this therapy can be
assessed through direct observation of respiratory effort and breath sounds that indicate a
significant decrease in air movement, such as
audible wheezing or stridor.
In patients who require bronchodilator therapy for COVID-19, the ideal practice is to use
patient-specific MDIs. This typical practice
may not be possible during a time of increased
use of MDIs throughout the country and with
limited availability of the medication. As a
result, alternative strategies must be considered. Several approaches have been proposed
to conserve the supply of MDIs, including using
a patient’s own supply whenever possible and
evaluating common canister protocols.8 The
common canister process uses a single MDI
canister with a patient-specific spacer device

420

to administer doses of bronchodilator medication to multiple patients after being disinfected with an alcohol prep pad before and after
each treatment. However, there is concern of
spreading infection between patients if the
MDI is not properly cleaned or stored correctly when using the common canister method.9
Patients who receive MDIs while hospitalized
often do not require the full amount of drug
contained in the canister, leading to significant
drug waste when these patient-specific MDIs
are discarded after hospital discharge.
An alternative program of canister reassignment is proposed to address concerns for
infection prevention, HCW safety, cross-contamination of MDIs and the impending shortage of MDIs due to the COVID-19 pandemic.
Canister reassignment is distinguished from
common canister protocols by utilizing both
a patient-specific MDI and spacer during the
inpatient stay. After hospital discharge, the inhaler is deconstructed and cleaned per hospital
protocol. This process minimizes waste of any
remaining drug and aids in enhanced infection
prevention by allowing a patient-specific MDI
to remain secured with the patient in the room
until discharge. Here we describe our development and rapid implementation of a MDI canister reassignment process during the COVID-19
pandemic and the effect of this process on the
use of MDIs.

Methods

We developed a MDI canister reassignment
process in response to the COVID-19 pandemic.
This guidance process was intended for facilities affiliated with our health care system. This
system includes 185 locally-managed hospitals
ranging in size from 26 to 1,000 beds across 21
states; facility types include community hospitals, academic health centers and large, tertiary-referral hospitals.
The comprehensive MDI canister reassignment
process consists of 4 components: preservation of supply, reassignment workflow, canister
cleaning and operational integration.

Preservation of Supply

Criteria were established to identify patients
appropriate for MDI use. (Table 1) These criteria
minimized the use of inhalers in patients who
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Table 1. Delivery device recommendations for specific patient populations during the COVID-19
pandemic.
Age

Specific Population

Nebulizer†

MDI

Canister
Reassignment*

Common
Canister†

Option

Option –
Reserve for PUI
or Confirmed
COVID-19 Pts

Option

Not
Preferred

COVID-19 Person Under Investigation (PUI)

Avoid Use

Option

Option

Not
Preferred

Non-ventilated
COVID-19 Patient

Avoid Use

Option

Option

Not
Preferred

Optional in a
closed circuit
ventilator‡

Option

Option

Not
Preferred

Option

Option –
Reserve for PUI
or Confirmed
COVID-19 Pts

Option

Not
Preferred

Avoid Use

Option

Option

Not
Preferred

Adult
Non-COVID-19 Patient
Patients

Ventilated COVID-19
Patient
Pediatric Pediatric Confirmed
Patients Non-COVID-19

Pediatric COVID-19
Person Under Investigation or Confirmed**

*Note Canister Reassignment is DIFFERENT than Common Canister
**Pediatric patients are less likely to be hospitalized for COVID-19 than adults
†Nebulizer and common canister have limited utility in a post-COVID-19 health care system with limited available testing
and the potential delay in diagnosis.
‡Nebulizer for ventilated COVID-19 patients: if using aerosol, ensure use of closed circuit system with filtered exhalation
and must not require breaking the circuit to administer. Consider using timed delivery device (such as in line MDI) in
order to minimize time spent in the room.6-7

are not suspected of or confirmed as having
COVID-19 to conserve supply.
Bronchodilator utilization was evaluated for
opportunities to optimize ordering and prescribing practices. Patients with underlying respiratory diseases like asthma and COPD were
continued on their maintenance medications.
As severe COVID-19 generally results in ARDS,
bronchodilators are typical of little benefit in
ARDS for patients without underlying lung
disease, and their use was not recommended.1,2
Bronchodilators were recommended to be
reserved for bronchoconstriction. If a bronchodilator was used and not found to be effective
(e.g., due to the patient having ARDS rather
than bronchoconstriction), discontinuation was
considered.
Whenever possible, the use of the patient’s
home MDI was recommended in both the
emergency department and inpatient areas.

This recommendation reduced demand and
impact on hospital MDI supply but required a
process for verification and patient-specific
labeling of home MDIs to ensure safe medication use.
Finally, the elimination of one-time use orders
for MDIs was encouraged. One-time orders
were considered a waste of resources in all
but emergent circumstances. Such orders
increased the burden of cleaning and reassignment for short term therapy.

MDI canister reassignment process

Reassignment workflow
Canister reassignment differs from common
canister use. Common canister programs
use individual patient spacers but use the
same canister for multiple patients. Canister
reassignment programs, however, use a patient-specific MDI during the inpatient stay.
The guidelines for the recommended workflow
421
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Table 2. Guidelines for canister reassignment workflow.
Canister reassignment workflow
Patient-specific MDI is used for the duration of inpatient stay
MDI is labeled and remains secured in the room with the patient during the stay
Upon discharge the canister is removed, entire MDI (canister, outside plastic portion, etc.) is
cleaned thoroughly per facility-specific process and returned to pharmacy
Spacer is disposed of after discharge
Pharmacy reassigns the canister for a different patient
A new spacer is used for each patient
for canister reassignment is provided in Table 2.
MDI canister cleaning process
The recommended MDI canister cleaning
process involves deconstructing the inhaler by
separating the metal medication canister and
actuator/mouthpiece and cleaning the device
parts with 70% alcohol.10 Other disinfecting
solutions, such as quaternary ammonia compounds, were not recommended as a soak
for cleaning the MDI canister or parts of the
delivery device. These products (undiluted or
diluted) may be harmful if ingested and may
compromise the integrity of the plastic pieces.11
In addition to cleaning, hospitals were encouraged to allow a rest period after disinfection
using the process outlined above and before
reassignment of the MDI canister. Of note, the
rest time may vary based on the viral pathogen;
for SARS-CoV-2, a rest period of 72–360 hours
(3–5 days) was recommended. This rest period
allowed time between disinfection and re-use,
providing an additional opportunity for the
virus to expire on surfaces and was dependent
on MDI supply and utilization. If the nozzle
could not be appropriately cleaned, the MDI
was not used for canister reassignment.12
Operational integration
Current administration, billing, storage and
infection control practices were evaluated to
identify gaps in processes and workflow. Based
on this evaluation, policies were created to address workflow, protocol development, infection control practices, education and outcome
metrics.

Results

As a health system, we incorporated innovative strategies to conserve our MDI supply. The
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guidance was distributed across the health
system for the MDI reassignment process, as
described in this article.
To evaluate the use of the MDI reassignment
process and nebulizer use, administration data
was reviewed from 162 hospitals across the
health system from January 1st to August 31st,
2020. (Figure 1) On average, 98% of patients
received a nebulizer vs. an MDI prior to March
6. The initial guidance released March 6th
recommended to discontinue using nebulizers
in COVID-19 persons under investigation (PUIs)
or positive patients. From March 6th to March
31st, patients receiving nebulizers decreased by
60%. Nebulizer usage was at its lowest on April
11th, which was 67% of the usage on March 6th.
This decline was sustained with a greater than
50% reduction through August 31st. The reduction in nebulizers followed the COVID-19 trends
that were seen within the affiliated hospitals.

Discussion

During the COVID-19 pandemic, the rapid implementation of the MDI reassignment process
has proved vital for the continued support
of clinical care and infection prevention. The
number of patients on a nebulizer decreased by
60% from March 6th to March 31st and stayed
reduced by >50% for the entire monitoring
period. This significant reduction in nebulizer
utilization correlates with the initial surge of
COVID-19 patients seen across the health care
system.
From our experience with the development
of the MDI reassignment process, we have
observed a need for collaboration between
various groups. For others considering a similar
process, interdisciplinary planning teams should
be formed that include, at a minimum, nursing,
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Figure 1. Nebulizer Use and COVID-19 Persons Under Investigation or Positive Patients
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respiratory therapy, infection preventionists,
providers and pharmacists. Collaboration between nursing and respiratory therapy can help
ensure patient-specific inhalers remain with a
patient upon transfer within the hospital. Pharmacists and providers should be engaged in the
selection of therapeutic interchanges based
on MDI product availability. For low use areas,
MDIs should be dispensed from the pharmacy,
rather than stocked in automated dispensing
cabinets, to conserve inventory and consolidate
stock. If MDIs are stocked in automated dispensing cabinets, someone should do a blind
count for removal so that accurate inventory
tracking occurs and diversion is prevented. This
careful tracking aids in monitoring utilization
and in proactive inventory management.

should be followed to clean MDI canisters outside of the medication room, and then return
them to the pharmacy for reassignment. We
recommend spacers be discarded.

The interdisciplinary team should assess policies and procedures to ensure basic infection
prevention and control practices occur between
patients to minimize cross-contamination risk
when using reusable medical devices.12 Canisters should be restricted to 1 patient at a time,
cleaned thoroughly upon discharge and placed
back into common stock for use. The canister
should be labeled and remain secured in the
patient room during the inpatient stay. Only
spacers with a one-way exhalation valve should
be used. After discharge, the hospital process

Another challenge was a lack of formal guidance statements from trusted medication
safety organizations on MDI disinfection steps,
particularly soaking procedures. The literature
has primarily focused on common canister use
rather than canister reassignment. Common
canister disinfection does not incorporate a
soaking step, which limits the evidence that can
be drawn upon to support the cleaning process
of MDIs with soaking.

Several key lessons have been learned following the implementation of this process. First,
we observed a need to communicate that 70%
isopropyl alcohol is an effective disinfection
agent that kills the virus that causes COVID-19
infection, as a common misconception is that
alcohol would not be virucidal.5,10,12-15 This misconception has undermined the confidence of
frontline health care workers in the effectiveness of the MDI disinfection process. Additional education has been necessary to combat this
misconception.
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Conclusion

We were able to develop a MDI reassignment
process that allows for increased MDI use
during the COVID-19 pandemic. This process
allows the continued delivery of pharmacologic
bronchodilator therapy for COVID-19 patients.
It also represents an important infection prevention strategy needed to protect our healthcare providers.
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